Day 66 5 x 10 8 cells/m 2 
Cells will be resuspended in a volume of 5-20ml. 
6.2 Patients will be premedicated with Benadryl 1 mg/kg IV and Tylenol lOmg/kg 
PO 
6.3 Patients may receive CTLs in the medicine room if they are an outpatient. 
Monitoring will be undertaken according to institutional standards for 
administration of blood products with the exception that the injection will be 
given by a physician. Antiemetics inappropriate dosage for each patient will be 
prescribed as necessary. 
6.4 Patients will receive supportive care for acute or chronic toxicity, including blood 
components or antibiotics, and other intervention as appropriate. 
6.5 All treatments will be given at St. Jude Childrens' Research Hospital. 
7.0 PATIENT EVALUATION 
7. 1 A complete history and physical examination is necessary prior to administration of 
CTLs on Day 45. 
7.2 Other Studies 
7.2.1 The following investigations will be obtained pre infusion, then 3 x weekly for 
6 weeks, then weekly for 6 weeks then monthly for 1 year. 
CBC and diff 
Urinalysis 
BUN, creatinine, bilirubin, SGOT,SGPT, alkaline phosphatase, Na, K, Cl, C0 2 , 
albumin, total protein, glucose. 
7.2.2 The following investigations will be obtained pre infusion, then weekly for 6 
weeks, monthly for 1 year and yearly for 10 years. 
Peripheral Blood in preservative free heparin (20 ml for BMT lab). This blood 
will be used for the following immunological and marker gene studies. 
Immunophenotyping 
Cytotoxicity assays 
T cell receptor repertoire analysis 
EBV DNA content 
Analysis for the marker gene by PCR and reverse transcriptase assay will be 
done for 10 years. 
[208] 
Recombinant DNA Research, Volume 17 
